BARD1 completed the acquisition of Sienna Cancer Diagnostics for $23m.

BARD1, a life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer, completed the acquisition of Sienna Cancer Diagnostics, a provider of health care services that offers pharmaceutical and biotechnology research and development, for $23m. “Sienna’s in-market bladder cancer test and new molecular NETs technology combined with our strong cancer diagnostics pipeline and scientific expertise in tumour biology will create a larger and more diversified medtech company with a clear focus on delivering innovative cancer diagnostic products to help save patient lives," Leearne Hinch, BARD1 CEO.